Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

Robin L. Jones*, Mark J. Ratain, Peter J. O'Dwyer, Lillian L. Siu, Jacek Jassem, Jacques Medioni, Maja DeJonge, Charles Rudin, Michael Sawyer, David Khayat, Ahmad Awada, Judith M. P. G. M. de Vos-Geelen, T. R. Jeffry Evans, Jennifer Obel, Bruce Brockstein, Jacques DeGreve, Jean-Francois Baurain, Robert Maki, David D'Adamo, Mark DicksonSamir Undevia, David Geary, Linda Janisch, Philippe L. Bedard, Albiruni R. Abdul Razak, Rebecca Kristeleit, Joanna Vitfell-Rasmussen, Ian Walters, Stan B. Kaye, Gary Schwartz

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)132-139
Number of pages8
JournalEuropean Journal of Cancer
Volume120
DOIs
Publication statusPublished - Oct 2019

Keywords

  • Brivanib
  • Solid tumours
  • Randomised discontinuation trial
  • FGF2 status
  • Sarcomas
  • Ovarian cancer
  • GROWTH-FACTOR RECEPTOR-2
  • SOFT-TISSUE SARCOMA
  • INHIBITOR
  • PAZOPANIB

Cite this

Jones, R. L., Ratain, M. J., O'Dwyer, P. J., Siu, L. L., Jassem, J., Medioni, J., DeJonge, M., Rudin, C., Sawyer, M., Khayat, D., Awada, A., de Vos-Geelen, J. M. P. G. M., Evans, T. R. J., Obel, J., Brockstein, B., DeGreve, J., Baurain, J-F., Maki, R., D'Adamo, D., ... Schwartz, G. (2019). Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European Journal of Cancer, 120, 132-139. https://doi.org/10.1016/j.ejca.2019.07.024